Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

By D. Lavanchy. Journal of Viral Hepatitis, 2004

2,779 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/dfb3a94dc4fd0b4ead53350caa55294f2b51c51e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis (2017, background): “[17,18] Chronic infection with HBV increases the relative risk for developing HCC 15–20‐fold with a mortality rate of approximately 30%–50% among all cases of chronic HBV infection.[19,20] Accordingly, regions endemic for”
Hepatocellular carcinoma pathogenesis: from genes to environment (2006, background): “Approximately 30–50% of HBV-related deaths are attributable to HC”
Chronic hepatitis B: Update 2009 (2009, neutral): “Aliment Pharmacol Ther 2006;23(8):1031-1041.”
The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001 -- Global Burden of Disease and Risk Factors (2006, methodology): “Available data on the prevalence of chronic hepatitis B and hepatitis C infection were used together with disease models to estimate regional incidence and mortality rates (Global Burden of Hepatitis C Working Group 2004; Lavanchy 2004; WHO 2002a, 2002b).”
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus (2012, neutral): “Individuals coinfected with HBV and HDV are at greater risk for rapid progression and severe disease ( Lavanchy, 2004 ; Hughes et al., 2011 ).”
Epidemiology and Prevention of Hepatitis B Virus Infection (2005, background): “By May 2002, 154 countries had routine infant immunization with hepatitis B vaccine [69].”
Why do viruses cause cancer? Highlights of the first century of human tumour virology (2010, background): “Vaccination programmes against two human tumour viruses, hepatitis B virus (HBV) and human papillomavirus (HPV), have already begun to alter age-old cancer patterns on an international scal”
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B (2010, background): “The reasons for treatment discontinuation were: completion of treatment in the opinion of the investigator (12), progression of CHB (1); death (5); loss to follow-up (2); patient noncompliance (1); withdrawal of consent (14); minimal virologic response (3); and other (9).”
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. (2006, background): “The widespread application of therapeutic interventions also has the potential to accelerate the declines in end-stage liver disease that will eventually follow from hepatitis B vaccination and other primary prevention efforts [104,107].”
Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “The prevalence of HBsAg varies greatly across countries, with high prevalence of HBsAg-positive persons defined as 8%, intermediate as 2% to 7%, and low as <2%.((21,22)) In developed countries, the prevalence is higher among those who immigrated from high- or intermediate-prevalence countries and in”
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “Low-prevalence (\2 %) regions included Australia and New Zealand, although prevalence has increased in recent years due to immigrants from high-prevalence countries [7, 8].”